Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Barry E. Kennedy; Maryanne Sadek; Manal O. Elnenaei; Anthony Reiman; Shashi A. Gujar

doi:10.1016/j.trecan.2019.11.005

Targeting NAD⁺ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Barry E. Kennedy, Maryanne Sadek, Manal O. Elnenaei, Anthony Reiman, Shashi A. Gujar

Medicine

Research output: Contribution to journal › Short survey › peer-review

16 Citations (Scopus)

Abstract

Antibodies targeting CD38, a NAD⁺-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD⁺ to enhance the efficacy of anti-CD38-based immunotherapies in MM.

Original language	English
Pages (from-to)	9-12
Number of pages	4
Journal	Trends in Cancer
Volume	6
Issue number	1
DOIs	https://doi.org/10.1016/j.trecan.2019.11.005
Publication status	Published - Jan 2020

Bibliographical note

Funding Information:
This work was supported by grants from the Canadian Cancer Society (CRS), the Canadian Cancer Society Research Institute (CCSRI), the Canadian Institutes of Health Research (CIHR), and the Beatrice Hunter Cancer Research Institute (BHCRI) to S.A.G. B.E.K. is a trainee in the Cancer Research Training Program (CRTP) of the BHCRI with funding from the Terry Fox Research Institute (TFRI). S.A.G. is supported by Dalhousie Medical Research Foundation (DMRF).

Publisher Copyright:
© 2019

ASJC Scopus Subject Areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2019.11.005

Cite this

@article{99780803191a4a6cac80edcddd8ed129,

title = "Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma",

abstract = "Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.",

author = "Kennedy, {Barry E.} and Maryanne Sadek and Elnenaei, {Manal O.} and Anthony Reiman and Gujar, {Shashi A.}",

note = "Funding Information: This work was supported by grants from the Canadian Cancer Society (CRS), the Canadian Cancer Society Research Institute (CCSRI), the Canadian Institutes of Health Research (CIHR), and the Beatrice Hunter Cancer Research Institute (BHCRI) to S.A.G. B.E.K. is a trainee in the Cancer Research Training Program (CRTP) of the BHCRI with funding from the Terry Fox Research Institute (TFRI). S.A.G. is supported by Dalhousie Medical Research Foundation (DMRF). Publisher Copyright: {\textcopyright} 2019",

year = "2020",

month = jan,

doi = "10.1016/j.trecan.2019.11.005",

language = "English",

volume = "6",

pages = "9--12",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

AU - Kennedy, Barry E.

AU - Sadek, Maryanne

AU - Elnenaei, Manal O.

AU - Reiman, Anthony

AU - Gujar, Shashi A.

N1 - Funding Information: This work was supported by grants from the Canadian Cancer Society (CRS), the Canadian Cancer Society Research Institute (CCSRI), the Canadian Institutes of Health Research (CIHR), and the Beatrice Hunter Cancer Research Institute (BHCRI) to S.A.G. B.E.K. is a trainee in the Cancer Research Training Program (CRTP) of the BHCRI with funding from the Terry Fox Research Institute (TFRI). S.A.G. is supported by Dalhousie Medical Research Foundation (DMRF). Publisher Copyright: © 2019

PY - 2020/1

Y1 - 2020/1

N2 - Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.

AB - Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.

UR - http://www.scopus.com/inward/record.url?scp=85077168297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077168297&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2019.11.005

DO - 10.1016/j.trecan.2019.11.005

M3 - Short survey

C2 - 31952784

AN - SCOPUS:85077168297

SN - 2405-8033

VL - 6

SP - 9

EP - 12

JO - Trends in Cancer

JF - Trends in Cancer

IS - 1

ER -